Holen Sie sich die Stockscreener-App
27.88
2.42%
-0.69
Handel nachbörslich:
27.50
-0.38
-1.36%
Schlusskurs vom Vortag:
$28.57
Offen:
$28.3
24-Stunden-Volumen:
1.29M
Relative Volume:
0.65
Marktkapitalisierung:
$2.01B
Einnahmen:
Nettoeinkommen (Verlust:
$-368.95M
KGV:
-5.0277
EPS:
-5.5453
Netto-Cashflow:
$-293.81M
1W Leistung:
-6.69%
1M Leistung:
-12.24%
6M Leistung:
-34.00%
1J Leistung:
-8.62%
1-Tages-Spanne:
$27.50
$28.40
1-Wochen-Bereich:
$26.38
$29.49
52-Wochen-Spanne:
$23.05
$56.05
Vera Therapeutics Inc Stock (VERA) Company Profile
Firmenname
Vera Therapeutics Inc
Sektor
Branche
Telefon
650-770-0077
Adresse
2000 SIERRA POINT PARKWAY, SUITE 1200, BRISBANE
Compare VERA vs VRTX, MRNA, REGN, ARGX, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
VERA
Vera Therapeutics Inc
|
27.88 | 2.01B | 0 | -368.95M | -293.81M | -5.5453 |
VRTX
Vertex Pharmaceuticals Inc
|
499.74 | 126.66B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
218.01 | 87.04B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
790.74 | 81.41B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
819.14 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
369.06 | 41.75B | 5.76B | 514.49M | 1.10B | 4.4813 |
Vera Therapeutics Inc Stock (VERA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-10-12 | Eingeleitet | Leerink Partners | Market Perform |
| 2026-03-11 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
| 2025-10-16 | Eingeleitet | BofA Securities | Buy |
| 2025-08-04 | Herabstufung | Wolfe Research | Outperform → Peer Perform |
| 2025-05-05 | Fortgesetzt | H.C. Wainwright | Buy |
| 2025-02-04 | Eingeleitet | Wolfe Research | Outperform |
| 2025-01-28 | Eingeleitet | Goldman | Buy |
| 2024-11-21 | Eingeleitet | Wells Fargo | Overweight |
| 2024-10-16 | Eingeleitet | Scotiabank | Sector Outperform |
| 2024-01-25 | Eingeleitet | Oppenheimer | Outperform |
| 2024-01-08 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2023-12-18 | Eingeleitet | Raymond James | Outperform |
| 2023-11-10 | Hochstufung | Jefferies | Hold → Buy |
| 2023-08-16 | Eingeleitet | Guggenheim | Buy |
| 2023-01-04 | Herabstufung | Jefferies | Buy → Hold |
| 2023-01-04 | Herabstufung | Wedbush | Outperform → Neutral |
| 2022-07-12 | Eingeleitet | JP Morgan | Overweight |
| 2022-05-02 | Eingeleitet | H.C. Wainwright | Buy |
| 2022-04-19 | Eingeleitet | Wedbush | Outperform |
Alle ansehen
Vera Therapeutics Inc Aktie (VERA) Neueste Nachrichten
Vera Therapeutics, Inc. (VERA) Stock Price, News, Quote & History - Yahoo! Finance Canada
Five new hires at Vera Therapeutics received share options and awards that vest over four years. - Stock Titan
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - globenewswire.com
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Vera Therapeutics (NASDAQ: VERA) CEO exercises options and sells shares under preset trading plan - Stock Titan
Vera Therapeutics CFO Young Joseph R Exercises 5,000 Stock Options at $3.94 (NASDAQ: VERA) - Kalkine Media
Vera Therapeutics (VERA) finance SVP adds 5,000 shares - Stock Titan
Vera Therapeutics at Cantor Fitzgerald conference: launch gains traction By Investing.com - Investing.com Canada
Vera Therapeutics at Cantor Fitzgerald conference: launch gains traction By Investing.com - Investing.com India
Centrus Announces Proposed Public Underwritten Offering of Class A Common Stock and Warrants - Yahoo Finance
Vera Therapeutics CEO Marshall Fordyce Executes 18,500 Share Sale Under 10b5-1 Trading Plan - Kalkine Media
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Discipline and Rules-Based Execution in VERA Response - Stock Traders Daily
Vera Therapeutics (NASDAQ: VERA) insider to sell tens of thousands of shares - Stock Titan
Vera Therapeutics stock gains after fresh analyst support - ad-hoc-news.de
Vera Therapeutics to Participate at Upcoming Investor Conferences - manilatimes.net
Vera Therapeutics to Participate at Upcoming Investor Conferences - GlobeNewswire
Vera Therapeutics to Participate at Upcoming Investor Conferences - Yahoo Finance
Vera Therapeutics options activity points to institutional bullish call spread on September strikes - investing.com
Nancy Lee Boman Net Worth (2026) - GuruFocus
Vera Therapeutics (NASDAQ:VERA): What Could Drive the Next Move? - Kalkine Media
What Vera Therapeutics (VERA)'s Widening Losses and Cash Burn Mean For Shareholders - Sahm
Vera Therapeutics, Inc. (NASDAQ:VERA) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
H.C. Wainwright Maintains Vera Therapeutics(VERA.US) With Buy Rating, Cuts Target Price to $90 - Moomoo
What Vera Therapeutics (VERA)'s Widening Losses and Cash Burn Mean For Shareholders - simplywall.st
Bank of America Corp DE Has $23.72 Million Stake in Vera Therapeutics, Inc. $VERA - MarketBeat
Vera Therapeutics upgraded to Buy after FDA nod for TRUTAKNA and positive kidney function data. - Pluang
Vera Therapeutics: FDA's eGFR Analysis Supports A Speculative Buy (NASDAQ:VERA) - Seeking Alpha
Wedbush Reiterates Neutral Rating for Vera Therapeutics (NASDAQ:VERA) - MarketBeat
J.P. Morgan Maintains Vera Therapeutics(VERA.US) With Buy Rating, Cuts Target Price to $76 - Moomoo
Vera Therapeutics Stock (VERA) Opinions on Positive eGFR Data Release - Quiver Quantitative
Vera Therapeutics Shares Up 9.7% as $425,000 Drug Launch Puts Focus on Cash Reserves - TechStock²
Vera Therapeutics Climbs as Investors React to TRUTAKNA Launch Progress and Near-Term IgAN Milestones - Quiver Quantitative
Kynam Capital (VERA) now holds 4.01% beneficial stake in Vera Therapeutics - Stock Titan
Vera Therapeutics (NASDAQ:VERA) Shares Gap UpHere's Why - MarketBeat
HC Wainwright Has Positive Estimate for VERA Q3 Earnings - MarketBeat
Vera stock rises on FDA review for kidney drug (VERA:NASDAQ) - Seeking Alpha
Is Vera Therapeutics (VERA) Undervalued On FDA Approval For TRUTAKNA? - Sahm
(VERA) Volatility Zones as Tactical Triggers - Stock Traders Daily
Vera Therapeutics president and CEO Marshall Fordyce sells $701,769 in stock - Investing.com
Vera Therapeutics president and CEO Marshall Fordyce sells $1.96m in stock - Investing.com
Vera Therapeutics CEO Marshall Fordyce sells $679,747 in stock - investing.com
Vera Therapeutics president and CEO Marshall Fordyce sells $1.96m in stock - Investing.com Nigeria
Vera Therapeutics president and CEO Marshall Fordyce sells $701,769 in stock - Investing.com Canada
Vera Therapeutics president and CEO Marshall Fordyce sells $1.96m in stock - Investing.com South Africa
Vera Therapeutics president and CEO Marshall Fordyce sells $701,769 in stock - Investing.com South Africa
Vera Therapeutics president and CEO Marshall Fordyce sells $1.96m in stock - Investing.com India
Vera Therapeutics president and CEO Marshall Fordyce sells $701,769 in stock - Investing.com Australia
Vera Therapeutics president and CEO Marshall Fordyce sells $701,769 in stock - Investing.com India
Vera Therapeutics CEO Marshall Fordyce sells $679,747 in stock - Investing.com
Finanzdaten der Vera Therapeutics Inc-Aktie (VERA)
Umsatz
Nettogewinn
Free Cashflow
ENV
Vera Therapeutics Inc-Aktie (VERA) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Fordyce Marshall | PRESIDENT AND CEO |
Sep 15 '26 |
Sale |
37.00 |
18,500 |
684,500 |
235,244 |
| Young Joseph R | SVP, FINANCE, CHIEF ACCT OFFCR |
Sep 11 '26 |
Option Exercise |
3.94 |
5,000 |
19,698 |
80,754 |
| Fordyce Marshall | PRESIDENT AND CEO |
Sep 02 '26 |
Sale |
35.12 |
18,500 |
649,642 |
235,244 |
| MARSHALL FORDYCE | Director |
Sep 02 '26 |
Proposed Sale |
34.23 |
64,750 |
2,216,392 |
0 |
| Fordyce Marshall | PRESIDENT AND CEO |
Sep 02 '26 |
Option Exercise |
2.90 |
18,500 |
53,591 |
253,744 |
| Fordyce Marshall | PRESIDENT AND CEO |
Jul 07 '26 |
Sale |
42.30 |
46,250 |
1,956,187 |
151,994 |
| MARSHALL FORDYCE | Director |
Jun 23 '26 |
Proposed Sale |
38.43 |
74,000 |
2,843,820 |
0 |
| Fordyce Marshall | PRESIDENT AND CEO |
Jun 23 '26 |
Sale |
37.93 |
18,500 |
701,769 |
198,244 |
| Fordyce Marshall | PRESIDENT AND CEO |
May 12 '26 |
Sale |
36.74 |
18,500 |
679,747 |
216,744 |
| MARSHALL FORDYCE | Director |
May 12 '26 |
Proposed Sale |
36.61 |
18,500 |
677,285 |
0 |
11.99%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):